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Abstract
Background—Invasive group A Streptococcus (GAS) infections are associated with significant 
morbidity and mortality rates. We report the epidemiology and trends of invasive GAS over 8 
years of surveillance.
Methods—From January 2005 through December 2012, we collected data from the Centers for 
Disease Control and Prevention’s Active Bacterial Core surveillance, a population-based network 
of 10 geographically diverse US sites (2012 population, 32.8 million). We defined invasive GAS 
as isolation of GAS from a normally sterile site or from a wound in a patient with necrotizing 
fasciitis (NF) or streptococcal toxic shock syndrome (STSS). Available isolates were emm typed. 
We calculated rates and made age- and race-adjusted national projections using census data.
Results—We identified 9557 cases (3.8 cases per 100 000 persons per year) with 1116 deaths 
(case-fatality rate, 11.7%). The case-fatality rates for septic shock, STSS, and NF were 45%, 38%, 
and 29%, respectively. The annual incidence was highest among persons aged ≥65 years (9.4/100 
000) or <1 year (5.3) and among blacks (4.7/100 000). National rates remained steady over 8 years 
of surveillance. Factors independently associated with death included increasing age, residence in 
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a nursing home, recent surgery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, 
emm type 1 or 3, and underlying chronic illness or immunosuppression. An estimated 10 649–13 
434 cases of invasive GAS infections occur in the United States annually, resulting in 1136–1607 
deaths. In a 30-valent M-protein vaccine, emm types accounted for 91% of isolates.
Conclusions—The burden of invasive GAS infection in the United States remains substantial. 
Vaccines under development could have a considerable public health impact.
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Invasive infections caused by group A Streptococcus (GAS) include bacteremic pneumonia, 
sepsis, necrotizing fasciitis (NF), streptococcal toxic shock syndrome (STSS), and focal 
infections, such as arthritis and bacteremic skin and soft-tissue infections (SSTIs). GAS 
more commonly causes noninvasive infections such as pharyngitis, sometimes with 
suppurative (eg, otitis media) or nonsuppurative (eg, acute rheumatic fever, acute 
glomerulonephritis) complications. GAS infections are associated with substantial morbidity 
and mortality rates worldwide, with an estimated 500 000 deaths globally per year [1–4].
Management of invasive GAS infection relies heavily on timely diagnosis, appropriate 
antimicrobial therapy, and, in some cases (eg, NF), prompt surgical intervention [5]. There 
are few prevention tools other than recommendations for control of disease in nosocomial 
clusters and outbreaks in closed facilities [6, 7]. Several GAS vaccine candidates are 
currently under development [8–11], including a 30-valent vaccine covering M proteins 
common in North America and Europe and those considered “rheumatogenic” [12].
The Centers for Disease Control and Prevention (CDC) have conducted surveillance for 
invasive GAS infection since 1995 as part of the Active Bacterial Core surveillance (ABCs) 
of the Emerging Infections Programs Network [13]. We report the epidemiologic 
characteristics of invasive GAS infection in the United States for 2005–2012, evaluate trends 
in incidence since 2000, and estimate potential impact of the 30-valent vaccine [12] 
currently under development.
METHODS
Surveillance
Invasive GAS cases were identified through ABCs, a population-and laboratory-based 
surveillance system that tracks invasive GAS in 10 geographically disparate US sites, 
covering a population of 32.8 million (10.4% of the total US population) in 2012. ABCs 
defines an invasive GAS infection as isolation of GAS from a normally sterile body site (eg, 
blood or cerebrospinal fluid), or from a wound culture accompanied by NF or STSS, in a 
resident of the surveillance catchment population. The ABCs sites and counties in which 
surveillance has been consistent since 2005 include the areas around San Francisco Bay, 
California (3 counties), Denver, Colorado (5 counties), Atlanta, Georgia (20 counties), 
Baltimore, Maryland (6 counties), Portland, Oregon (3 counties), and Rochester and Albany, 
New York (15 counties); urban areas in Tennessee (11 counties); and the entire states of 
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Minnesota, New Mexico, and Connecticut. These areas were included for incidence rate and 
trend calculations. In 2010, Tennessee expanded its surveillance area to 20 counties; this 
larger surveillance area was included in descriptive analyses only. In trend analyses that 
included surveillance from 2000 through 2004, the 2 most recently added ABCs sites were 
excluded (Colorado joined ABCs in 2001, New Mexico in 2004).
Descriptive Epidemiology
Descriptive analyses included all cases with culture dates from 1 January 2005 through 31 
December 2012. Annual summary of overall disease rates are shared on the ABCs Web site 
[14]. For national rate and burden estimates, race- and age-specific disease rates were 
applied from the aggregate surveillance area to the age and racial distributions of the US 
population for each year. We used regional and national postcensal population estimates for 
each year as the denominator. All incidences are expressed as cases per 100 000 population 
per year. The Cochran-Armitage test was used to test the statistical significance of the linear 
trend in disease incidence from 2000 to 2012. Case patients with unknown race were 
distributed according to those with known race in each surveillance area and age category. 
Case-fatality rates (CFRs) were calculated using outcome at the time of discharge from 
hospital, emergency department, or clinic.
Case patients with GAS cultured from blood, but for whom no clinical syndrome was 
identified, were categorized as having bacteremia without a source. To allow comparisons 
with published ABCs GAS data from 1995–1999 [1] and 2000–2004 [2], we categorized 
clinical syndromes as described in previous reports, unless otherwise indicated. We 
compared clinical syndromes in children aged <10 years and adults aged ≥65 years with 
those in persons aged 10–64 years, using log binomial regression models. We also modeled 
the probability of death among case patients with a specific clinical syndrome using log 
binomial models and compared the CFR of the youngest and oldest age groups with that for 
patients aged 10–64 years.
Case patients who had undergone surgery in the 7 days preceding their first positive culture 
result were categorized as “recent surgery.” Any infection in a pregnant woman, whether 
specific to pregnancy (eg, endometritis, chorioamnionitis, septic abortion) or simply 
occurring during pregnancy, was considered “pregnancy related.” Hospital-onset infections 
were defined as infections in case patients hospitalized for ≥3 days before their positive 
GAS culture. Underlying conditions were grouped similarly to previously published data [1, 
2]. Two variables added to the ABCs case report form in 2009 were analyzed separately: 
chronic skin breakdown and septic shock syndrome. We modeled the probability that a case 
patient had a specific underlying condition using a log binomial model with surveillance 
area as the only covariate. We compared the proportions of case patients with an underlying 
condition in each site with the mean proportion having the underlying condition across all 
ABCs sites.
GAS Typing
All available GAS isolates were typed at the CDC’s Streptococcus laboratory after they were 
confirmed to be GAS. A combination of emm sequence typing and restriction profiling was 
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used to deduce emm types through 2007. Beginning in 2008, emm typing for all isolates was 
performed by sequencing the variable M serotype–specific region of the emm gene 
amplicons. The protocol for emm typing and a complete, downloadable listing of emm type 
sequences are available online [15, 16].
Estimates of Vaccine Benefit
To estimate the potential benefits of a multivalent vaccine, we used available emm typing 
results to calculate the proportions of cases and deaths by emm type in the proposed 30-
valent vaccine (types 1, 2, 3, 4, 5, 6, 11, 12, 14, 18, 19, 22, 24, 28, 29, 44, 49, 58, 73, 75, 77, 
78, 81, 82, 83, 87, 89, 92, 114, and 118) [12].
Predictors of Death
Predictors of death were evaluated using a logistic regression model. In this model we 
reclassified the clinical syndrome of case patients with multiple clinical syndromes; these 
cases were classified with the highest-severity syndrome, based on the CFR for case patients 
presenting with only 1 syndrome, and SSTIs (not including NF) were grouped into a single 
syndrome. Underlying illnesses and medical conditions known to increase risk for GAS 
infection were grouped into 4 categories: no underlying illness, skin condition (eg, burns, 
wounds, and chronic skin breakdown), chronic illness (eg, cirrhosis, obesity, diabetes, and 
chronic obstructive pulmonary disease), and immunosuppression (eg, sickle cell disease, 
nephrotic syndrome, human immunodeficiency virus [HIV]/AIDS, and cancer). A person 
with multiple underlying illnesses was placed in the category of highest severity based on 
the following decreasing levels of severity: immunosuppression, chronic illness, and skin 
condition.
The model included only case patients for whom information on all variables was available. 
We excluded case patients with an unknown outcome, those from a site that did not record 
information on HIV/AIDS status or collect GAS isolates, and those with no available isolate 
or with emm-nontypeable isolates. Variables associated with death (P < .20) in univariate 
analysis were entered in the multivariable model and retained if the P value was <.05. 
Collinearity and all 2-way interactions were evaluated. All analyses were conducted using 
SAS software, version 9.3.
RESULTS
Demographic Characteristics and Disease Rates
ABCs sites reported 9557 cases of invasive GAS infection during the 8-year surveillance 
period. GAS was most frequently isolated from blood (7837 cases; 82%), joint space (766 
cases; 8%), pleural fluid and tissue (249 cases; 3%), bone (175 cases; 2%), muscle (172 
cases; 2%), peritoneal fluid (134 cases; 1%), and cerebrospinal fluid (75 cases; 1%). For 
some patients, GAS was isolated from >1 site. The median age of case patients was 52 years 
(range, 0 days to 106 years); 54% were male. Sixty percent of patients were white; the 
remainder were black (16%), American Indian and Alaskan Native (4%), Asian and Pacific 
Islanders (3%), or unknown race (17%). The distribution of unknown race varied by site, 
ranging from 3% in Maryland to 41% in Oregon.
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Most case patients (n = 8814; 92.5%) were hospitalized (data missing/unknown for 27 
cases), and 1117 died (overall CFR, 11.7%). Compared with those not hospitalized, 
hospitalized case patients presented more frequently with pneumonia (16% vs 10%; P < .
001), SSTI (42% vs 23%; P < .001), and NF (7% vs 1%; P < .001) and less frequently with 
bacteremia without focus (23% vs 48%; P < .001). Outcomes were unknown for 9 patients 
(0.1%). CFR was highest among persons aged ≥85 years (26.1%) and lower among 
nonwhite than among white patients (10.3% vs 12.2%; relative risk, 0.84; 95% confidence 
interval, .73–.98; Figure 1). Adjusting for US racial and age distributions, we estimate that 
10 649–13 434 cases and 1136–1607 deaths due to invasive GAS occurred annually in the 
United States in 2005–2012.
Incidence Rates
Invasive GAS rates were bimodal, with a peak among children age <2 years (incidence, 
6.5/100 000 and 4.4/100 000 among nonwhites and whites, respectively) and a second, 
higher peak among those aged ≥50 years (8.1/100 000 and 7.2/100 000 among nonwhites 
and whites, respectively). Incidence rates were highest among patients aged >85 years 
(14.4/100 000), followed by adults aged 75–84 years (10.0/100 000), and then adults aged 
65–74 years (8.1/100 000; Figure 1). The annual incidence was higher among non-white 
patients (4.5/100 000) than among white patients (3.6/100 000; relative risk, 1.2; 95% 
confidence interval, 1.2–1.3).
The average annual incidence for the 8 years of surveillance was 3.8 invasive GAS cases per 
100 000 persons (range, 2.7–6.2/100 000; Table 1) and varied by site. Most sites had slight 
year-to-year variation. There was no statistically significant trend in rates among the 10 sites 
in continuous surveillance from 2005 to 2012 (P = .23) or among the 8 sites with continuous 
surveillance since 2000 (P = .57; Table 1). Most disease occurred in winter and early spring 
(Figure 2), a pattern consistent across syndromes and ABCs sites.
Underlying Disease
Information on underlying medical conditions known or suspected to increase risk of 
sporadic GAS infection was available for 9232 (97%) of the patients; 74% had ≥1 
underlying condition, and 45% had ≥2. Most common were diabetes, acute skin breakdown, 
heart disease, and smoking (Table 2). Underlying conditions (particularly injection drug use 
and chronic skin breakdown) varied significantly by site.
Clinical Syndromes
The distribution of clinical syndromes, by age group and CFR, are presented in Table 3; 
41% of patients presented with SSTIs, 25% with isolated bacteremia, and 16% with 
pneumonia. Compared with patients aged 10–64 years, those aged <10 years were more 
likely to present with meningitis and central nervous system infections, septic arthritis, 
osteomyelitis, abscesses, epiglottitis or otitis media, or isolated bacteremia. Patients aged 
≥65 years were more likely to present with pneumonia, bacteremia, or SSTIs. Those with 
septic shock, STSS, NF, meningitis, or pneumonia had the highest CFRs.
Nelson et al. Page 5
Clin Infect Dis. Author manuscript; available in PMC 2018 January 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Among the 8921 case patients for whom information was available (93%), 315 (3.5%) had 
undergone recent surgery (CFR, 11.8%). Among women of childbearing age (aged 15–44 
years), 246 (20.1%) of the invasive GAS infections were pregnancy related. Of case patients 
with available information, 358 (4.1%) had healthcare-associated disease, and 38 died (CFR, 
10.6%). The distribution of syndromes and CFRs were similar in healthcare-onset and 
community-onset cases (CFR, 10.6 vs 11.7%; P = .57).
Emm Sequence Types and Potential Vaccine-Preventable Disease
Of 9 states submitting isolates for evaluation, bacterial isolates were available for typing for 
86% of cases; only 4 could not be typed. The distribution of emm types varied by site and by 
year. Although 99 unique emm types were identified during 2005–2012, the 23 most 
common accounted for 92% of cases (Figure 3). Most common were emm types 1 (22%), 12 
(9%), 28 (8%), 89 (7%), and 3 (7%), which cumulatively accounted for 53% of isolates. The 
emm types in the proposed 30-valent vaccines accounted for 91% of all isolates, 92% of 
those with NF or STSS, and 96% of isolates among patients who died.
Predictors of Death
Increasing age, residence in a nursing home, recent surgery, presence of specific syndromes 
(septic shock, NF, meningitis, isolated bacteremia, or pneumonia), emm type 1 or 3, and 
either underlying chronic illness or immunosuppression were all independent predictors of 
death (Table 4). No statistically significant 2-way interactions were found.
DISCUSSION
Invasive GAS infections continue to have be associated with morbidity and mortality rates in 
the United States, with an estimated 10 649–13 434 cases resulting in 1136–1607 deaths 
each year. The estimated national incidence is similar to the incidence of invasive GAS in 
Canada (4.3/100 000) and many European countries (2–4/100 000) (CFR, 14%–19%) [17–
21]. However, substantially higher rates of disease have been documented in other 
geographic areas, including Fiji (9.9/100 000), North Queensland, rural Kenya, and New 
Zealand (7.9/100 000) [22–25], as well as in European countries experiencing outbreaks, 
including Iceland (1.1–4.0/100 000), Sweden (6.1/100 000), and Ireland (0.8–2.7/100 000) 
[26–28].
Although annual incidence rates varied by site—with the lowest mean rates reported in 
Georgia (2.7/100 000) and the highest in New Mexico (6.2/100 000)—none of the 10 ABCs 
sites showed significant changes in incidence over time. Moreover, when limiting our 
analysis to the 8 ABCs sites in continuous surveillance since 2000, we found no significant 
change in rates of invasive GAS infections during a 13-year period. The stability of national 
incidence is remarkable and may only decline with use of an effective vaccine. Continued 
surveillance is needed to detect any future increase in invasive GAS infections due to 
potential emerging strains.
Prior publications have shown that the incidence of invasive GAS is higher in persons aged 
≥65 years living in the community and in long-term-care facilities, in terms of both sporadic 
infections and outbreaks [29]. In our study, we further examined rates among the very 
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elderly; incidence peaked at 14/100 000 and the CFR reached 25% among those aged ≥85 
years. In addition, the CFRs for most syndromes increased with age and were dramatically 
higher among some: 70% of elderly patients presenting with STSS alone and 56% of those 
with NF as their only syndrome died of their infections. Given that the population of elderly 
individuals is growing in the United States [30], increased attention needs to be given to 
severe presentations in this population.
To reduce morbidity and mortality rates due to GAS infections, effective prevention tools are 
desperately needed. The current candidate GAS vaccines entering or nearing clinical study 
are the 30-valent N-terminal M-protein–based vaccine and the conserved M-protein vaccine 
(minimal epitope J8 vaccine) [31]. The 30-valent vaccine would cover 91% of GAS 
infections reported by ABCs surveillance. The United States and other high-income 
countries account for only a small proportion of the total burden of GAS disease, and 
significantly greater heterogeneity of emm types has been documented in low-income 
geographic regions [32]. Fortunately, the 30-valent vaccine has been shown to evoke cross-
opsonic bactericidal antibodies against a variety of nonvaccine serotypes, potentially 
increasing vaccine efficacy in developing countries [12, 33]. The addition of these 
nonvaccine emm types could increase the potential vaccine coverage of invasive GAS 
infections in the United States to 96%. Furthermore, other vaccines in development are 
based on conserved epitopes.
ABCs surveillance began formally tracking septic shock as a distinct syndrome in 2009. 
Septic shock had the highest CFR both when found along with another syndrome as well as 
when it was the only syndrome present. A more detailed chart review is necessary to identify 
any important clinical differences between physician-diagnosed “septic shock” and STSS 
(see STSS case definition [34]). The frequency with which providers use the standard 
clinical criteria to define STSS is unknown but is probably low; measuring physician-
diagnosed STSS alone may underestimate the burden of severe GAS infections significantly. 
Because there have been few new treatment options for severe GAS infections, approaches 
to both STSS and septic shock continue to rely on promoting routine infection control, 
prompt case identification, and prevention of secondary cases among postpartum and 
postsurgical patients, supportive care, antibiotics, intravenous immunoglobulin, and prompt 
surgical attention when needed [35].
Our identification of recent surgery as an independent predictor of death should further alert 
providers to consider the diagnosis of invasive GAS in these patients. Prompt recognition of 
GAS and institution of antimicrobial therapy may limit morbidity and mortality risks. 
Whereas the presence of “any skin condition” was not significantly associated with 
increased risk of death, this variable includes both chronic and acute skin conditions, which 
may obscure risks that attend specific skin conditions. Although most invasive GAS 
infections are sporadic, wounds (eg, surgical wounds and decubiti) have been recognized as 
a common risk factor for GAS infection in nosocomial outbreaks and outbreaks among 
persons living in nursing homes and other group settings [36–38]. Many severe infections 
have also been found to occur within 24–72 hours of nonpenetrating trauma that results in a 
deep hematoma [39].
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Our study highlights a consistent seasonal pattern of invasive GAS infections with a peak in 
winter and early spring and a nadir in the late summer and fall. A recent review of data from 
5 countries in Europe and a study in Sweden found similar seasonal patterns in all countries 
[18, 27]. One proposed mechanism for a seasonal relationship is concurrently circulating 
viral infections during high-incidence periods, along with effects of crowding and close 
contact due to increased time spent indoors. Crowding and exposure to children with 
pharyngitis—a major reservoir of GAS—have been recognized as significant risk factors for 
invasive GAS infections [40].
Rates of invasive GAS infection measured by ABCs are minimum estimates because ABCs 
captures only invasive infections with sterile-site isolates unless GAS cultures from wounds 
are accompanied by STSS or NF syndromes. Furthermore, standard ABCs methods 
probably underreport cases of STSS and NF because providers do not always use these 
specific terms to describe such cases in medical records [41].
In the United States, invasive GAS remains a serious infection associated with high 
mortality rates. With no new effective tools for disease prevention, rates have remained 
unchanged during the last 13 years. In this setting, more rapid recognition of severe GAS 
infections and prompt and appropriate treatments are needed. Given that the initial 
presentation of invasive GAS infections is often nonspecific and such infections can cause 
severe disease and death, vaccines are sorely needed. The emm types causing invasive GAS 
disease are the most prevalent causes of GAS pharyngitis [42]. Decreasing the impact of 
GAS pharyngitis alone in the United States through immunization with an M-protein 
vaccine would potentially be cost-effective and reduce the primary reservoir of invasive 
infections. In addition, vaccination may also reduce unnecessary antibiotic prescriptions for 
pharyngitis, leading to additional indirect benefits.
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Figure 1. 
Incidence and case-fatality rates (CFRs) of invasive group A Streptococcus infections by age 
group and race in 2005–2012. Race and age group-specific rates of disease were taken from 
the surveillance areas in continuous use since 2005. Unknown race data were distributed 
among known values in the surveillance areas.
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Figure 2. 
Seasonality of invasive group A Streptococcus infections in the United States, 2005–2012. 
Abbreviations on x-axis represent months (J, January; F, February; etc).
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Figure 3. 
Distribution of invasive group A streptococcal isolates from Active Bacterial Core 
surveillance among the 23 most common emm types found during 2005–2012; these 
included any emm type that comprised >1% of total isolates.
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Table 4
Independent Risk Factors Associated With Death Due to Invasive Group A Streptococcus Infection for Cases 
Reported in 2005–2012a
Variable Odds Ratio (95% CI)
Age group, y
 <18 0.83 (.46–1.52)
 18–34 Reference
 35–49 2.00 (1.30–3.08)
 50–64 2.80 (1.85–4.25)
 65–74 3.34 (2.15–5.17)
 ≥75 5.41 (3.53–8.27)
Race
 White Reference
 Nonwhite 0.91 (.74–1.12)
Sex
 Male Reference
 Female 1.04 (.88–1.23)
Recent surgeryb
 Yes 1.66 (1.06–2.61)
 No Reference
Nursing home residencec
 Yes 1.84 (1.38–2.44)
 No Reference
Syndrome
 Syndrome other than those listed below Reference
 Septic shock 9.11 (5.83–14.24)
 Necrotizing fasciitis 5.25 (3.15–8.77)
 Meningitis or CNS infection 4.12 (1.72–9.87)
 Pneumonia 3.44 (2.19–5.40)
 Bacteremia without source 3.20 (2.08–4.93)
 SSTI 0.92 (.58–1.48)
emm Type
 Not 1, 3, 12, 28, or 89 Reference
 1 1.39 (1.12–1.72)
 3 1.75 (1.30–2.36)
 12 1.08 (.79–1.48)
 28 1.00 (.72–1.42)
 89 0.92 (.65–1.30)
Health status
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Variable Odds Ratio (95% CI)
 No underlying illness Reference
 Skin conditiond 0.84 (.54–1.31)
 Chronic illness 1.37 (1.06–1.76)
 Immunosuppression 1.64 (1.24–2.18)
Abbreviations: CI, confidence interval; CNS, central nervous system; SSTI, skin and soft-tissue infection.
a
Data from New York and Connecticut were excluded, because deaths were associated with human immunodeficiency virus infection/AIDS were 
not reported (New York) or isolates were not available to enable emm typing (Connecticut).
bSurgery within 7 days before first positive culture.
c
Residence at time of first positive culture.
d
Includes penetrating and blunt trauma, burns, varicella, surgical wounds (within 7 days before first positive culture), and chronic skin condition.
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